YBSW 015
Alternative Names: YBSW-015Latest Information Update: 08 Jun 2022
At a glance
- Originator Yabao Pharmaceutical Group
- Class Antivirals; Bispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 11 May 2022 Preclinical trials in COVID-2019 infections in China (IV) (NCT05369754)
- 11 May 2022 Yabao Pharmaceutical plans a phase I trial for COVID-2019 infections (In volunteers) in China (IV) (NCT05369754)